Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 29Leukemia 8Leukemia, Myelomonocytic, Acute 6Leukemia, Monocytic, Acute 5Leukemia, Erythroblastic, Acute 5Congenital Abnormalities 5Myeloproliferative Disorders 4Leukemia, Megakaryoblastic, Acute 4Recurrence 3Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Promyelocytic, Acute 2Leukemia, Eosinophilic, Acute 2Leukemia, Biphenotypic, Acute 2Leukemia, Basophilic, Acute 2Neoplasms by Histologic Type 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Hepatocellular 1Blast Crisis 1

Interventions

tetulomab tetraxetan lu-177 2osimertinib 2fludarabine 2entinostat 2Pemetrexed 2Lutetium 2Carboplatin 2spartalizumab 1pembrolizumab 1nirogacestat 1interferon gamma-1b 1gilteritinib 1ficlatuzumab 1emvododstat 1denileukin diftitox 1atezolizumab 1Trabectedin 1Taxes 1Sunitinib 1Radiosurgery 1Oncolytic Virotherapy 1Nivolumab 1Lutetium-177 1Interleukin-2 1Interferon-gamma 1Immunotherapy 1Idarubicin 1HuMax-IL8 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms by Histologic Type × Idarubicin × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡